Abstract
Tumour antigen-induced inhibition of leucocyte adherence was modified for use in glass test tubes (Tube LAI assay) for the study of cell-mediated anti-tumour immunity to human malignant melanoma. Peripheral blood leucocytes (PBL) of 20 out of 25 patients (80%) with active malignant melanoma responded to an extract of malignant melanoma with LAI, whereas only 4-5% of 475 control subjects showed a response. The malignant melanoma patients reacted to both allogeneic and autologous extracts of malignant melanoma which indicates a common cross-reacting antigen. Malignant melanoma patients did not respond to unrelated tumour extracts. The LAI was mediated by PBL (monocytes) "armed" with cytophilic anti-tumour antibody specific for the sensitizing tumour antigen. The anti-tumour response of the malignant melanoma patients was dependent on the stage of the cancer, and 11 out of 13 Stage I patients had a positive NAI, whereas patients with disseminated cancer had decreased response. The diminished LAI in patients with large tumour burdens appeared to be the result of release of tumour antigen systemically. Also, surgery and chemotherapy depressed LAI. Although LAI was depressed after surgical excision of the cutaneous melanoma, most patients showed LAI 1-3 months later. Tumour-free melanoma patients monitored for one year by the Tube LAI assay showed a decline in their anti-tumour immunity 5-6 months after surgery. The NAI was low or negative after the 8th post-surgical month in tumour-free patients. Patients with residual malignant melanoma showed persistent or recurrent LAI after the 8th post-surgical month. LAI reactivity monitored after "curative" surgery for malignant melanoma may assist in determining whether the patient is tumour-free or has a recurrence.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 24 print issues and online access
$259.00 per year
only $10.79 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Additional information
This worlk was supported by the Medical Research Council of Canada.
Rights and permissions
About this article
Cite this article
Marti, J., Thomson, D. Anti-tumour immunity in malignant melanoma assay by tube leucocyte adherence inhibition. Br J Cancer 34, 116–133 (1976). https://doi.org/10.1038/bjc.1976.134
Issue Date:
DOI: https://doi.org/10.1038/bjc.1976.134
This article is cited by
-
Effects of anti-idiotype vaccine on tumour growth and on production of soluble factors modulating cell-mediated immunity in vitro
Cancer Immunology Immunotherapy (1991)
-
Leukocyte adherence inhibition in patients with nonmalignant disorders of the colon and colorectal cancer
Journal of Cancer Research and Clinical Oncology (1986)
-
Regulation of leukocyte glass adherence and tube leukocyte adherence inhibition (LAI) reactivity by serum factors in dogs with progressing or spontaneously regressing canine transmissible venereal sarcoma (CTVS)
Cancer Immunology, Immunotherapy (1985)
-
Cancer bowel disease: Cellular reactivity mediated by serum factors
Agents and Actions (1983)
-
The utilization of native glioma antigens in the assessment of cellular and humoral immune responses in malignant glioma patients
Acta Neurochirurgica (1981)